Therapeutic advances 1. Endothelin-targeted therapy Selective endothelin alpha receptor antagonists are potent vasodilators and may be a new treatment for patients with intractable hypertension. The most common adverse events reported are mild to moderate fluid retention and edema, heart failure in some patients, and high doses of hydrochlorothiazide or chlorothiazide and long-acting climbing diuretics may be considered in patients with combined diabetes, renal disease or coronary artery disease. 2, Percutaneous radiofrequency ablation to remove renal sympathetic nerves The invention of this technique is based on the presence of significant activation of the sympathetic nervous system in the state of intractable hypertension. The sympathetic efferent and afferent nerve fibers of the central nervous system form centers in the kidney, and this activation can be blocked by radiofrequency ablation of the renal sympathetic nerve. In fact sympathetic overactivation is not only a key factor in the development and progression of hypertension, but is also closely related to the development of chronic diseases such as insulin resistance, congestive heart failure, end-stage renal disease, obstructive sleep apnea syndrome, diuretic resistance and cardiorenal syndrome, and tachycardia. Selective resection of sympathetic nerves using interventional means undoubtedly provides a very good idea for the treatment of intractable hypertension. However, the treatment of intractable hypertension by percutaneous catheter renal sympathetic nerve radiofrequency ablation requires a lot of research work, mainly its efficacy and safety need to be verified in prospective randomized clinical trials; secondly, the screening of indications for the procedure, in addition to intractable hypertension, whether plasma Ang II, cardiac natriuretic factor, brain natriuretic factor, aldosterone and other clinical tests can be included in the indications needs to be further studied; finally, its contraindications These need a lot of animal experiments and clinical trials to further study and discover. The Rheos Pressure Reflex Hypertension Therapy System is an implantable device that activates the carotid sinus pressure reflex. It controls blood pressure by activating the carotid sinus pressure reflex through electrical stimulation, but large-scale trials are needed to clarify its safety and effectiveness. Although carotid pressure receptor stimulation can bring about a sustained decrease in blood pressure, its application is limited by the need for surgical exposure of the carotid artery, the risk of infection, and the frequent replacement of pulse generating devices.